Dogwood Therapeutics Inc.

News & Events

Press Releases

In The Media

1. Dogwood Therapeutics Announces First Quarter 2025 Financial Results

   GlobeNewswire MAY 8, 2025 9:00 AM EDT
   - Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron ® Chemotherap...
   READ ARTICLE

2. Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

   Newsfile MAY 1, 2025 8:30 AM EDT
   Alpharetta, Georgia--(Newsfile Corp. - May 1, 2025) - Dogwood Therapeutics, Inc. (NASDAQ: DWTX)...
   READ ARTICLE

3. Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

   GlobeNewswire APR 11, 2025 9:15 AM EDT
   ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the ȁ...
   READ ARTICLE

4. Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

   GlobeNewswire APR 3, 2025 9:00 AM EDT
   ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the ȁ...
   READ ARTICLE

5. Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

   GlobeNewswire MAR 31, 2025 3:45 PM EDT
   -Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron ® Chemotherapy...
   READ ARTICLE

6. Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

   GlobeNewswire MAR 18, 2025 8:45 AM EDT
   ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (ȁ...
   READ ARTICLE

7. Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

   GlobeNewswire MAR 13, 2025 9:00 AM EDT
   Proceeds from today’s financing, when added to existing cash, fund operations through Q1 2...
   READ ARTICLE

8. Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward

   GlobeNewswire MAR 12, 2025 8:30 AM EDT
   ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (ȁ...
   READ ARTICLE

9. Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

   GlobeNewswire JAN 21, 2025 9:15 AM EST
   ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the &#x...
   READ ARTICLE

10. Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

    GlobeNewswire NOV 18, 2024 8:45 AM EST
    - IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clin...
    READ ARTICLE